Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1968 1
1969 1
1970 1
1971 3
1972 1
1974 1
1975 1
1976 2
1977 7
1978 3
1979 3
1980 2
1981 2
1983 1
1984 5
1985 9
1986 7
1987 11
1988 7
1989 6
1990 12
1991 5
1992 10
1993 16
1994 15
1995 14
1996 25
1997 12
1998 13
1999 12
2000 19
2001 20
2002 13
2003 11
2004 16
2005 19
2006 18
2007 17
2008 17
2009 17
2010 19
2011 18
2012 23
2013 23
2014 21
2015 29
2016 33
2017 29
2018 31
2019 44
2020 51
2021 56
2022 4
Text availability
Article attribute
Article type
Publication date

Search Results

691 results
Results by year
Filters applied: . Clear all
Page 1
Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations.
Paik PK, Felip E, Veillon R, Sakai H, Cortot AB, Garassino MC, Mazieres J, Viteri S, Senellart H, Van Meerbeeck J, Raskin J, Reinmuth N, Conte P, Kowalski D, Cho BC, Patel JD, Horn L, Griesinger F, Han JY, Kim YC, Chang GC, Tsai CL, Yang JC, Chen YM, Smit EF, van der Wekken AJ, Kato T, Juraeva D, Stroh C, Bruns R, Straub J, Johne A, Scheele J, Heymach JV, Le X. Paik PK, et al. Among authors: conte p. N Engl J Med. 2020 Sep 3;383(10):931-943. doi: 10.1056/NEJMoa2004407. Epub 2020 May 29. N Engl J Med. 2020. PMID: 32469185 Free PMC article. Clinical Trial.
Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer.
André F, Ciruelos E, Rubovszky G, Campone M, Loibl S, Rugo HS, Iwata H, Conte P, Mayer IA, Kaufman B, Yamashita T, Lu YS, Inoue K, Takahashi M, Pápai Z, Longin AS, Mills D, Wilke C, Hirawat S, Juric D; SOLAR-1 Study Group. André F, et al. Among authors: conte p. N Engl J Med. 2019 May 16;380(20):1929-1940. doi: 10.1056/NEJMoa1813904. N Engl J Med. 2019. PMID: 31091374 Clinical Trial.
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation.
Robson M, Im SA, Senkus E, Xu B, Domchek SM, Masuda N, Delaloge S, Li W, Tung N, Armstrong A, Wu W, Goessl C, Runswick S, Conte P. Robson M, et al. Among authors: conte p. N Engl J Med. 2017 Aug 10;377(6):523-533. doi: 10.1056/NEJMoa1706450. Epub 2017 Jun 4. N Engl J Med. 2017. PMID: 28578601 Free article. Clinical Trial.
OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer.
Robson ME, Tung N, Conte P, Im SA, Senkus E, Xu B, Masuda N, Delaloge S, Li W, Armstrong A, Wu W, Goessl C, Runswick S, Domchek SM. Robson ME, et al. Among authors: conte p. Ann Oncol. 2019 Apr 1;30(4):558-566. doi: 10.1093/annonc/mdz012. Ann Oncol. 2019. PMID: 30689707 Free PMC article. Clinical Trial.
Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer.
Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S, Campone M, Petrakova K, Blackwell KL, Winer EP, Janni W, Verma S, Conte P, Arteaga CL, Cameron DA, Mondal S, Su F, Miller M, Elmeliegy M, Germa C, O'Shaughnessy J. Hortobagyi GN, et al. Among authors: conte p. Ann Oncol. 2018 Jul 1;29(7):1541-1547. doi: 10.1093/annonc/mdy155. Ann Oncol. 2018. PMID: 29718092 Free article. Clinical Trial.
Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: final overall survival results from SOLAR-1.
André F, Ciruelos EM, Juric D, Loibl S, Campone M, Mayer IA, Rubovszky G, Yamashita T, Kaufman B, Lu YS, Inoue K, Pápai Z, Takahashi M, Ghaznawi F, Mills D, Kaper M, Miller M, Conte PF, Iwata H, Rugo HS. André F, et al. Among authors: conte pf. Ann Oncol. 2021 Feb;32(2):208-217. doi: 10.1016/j.annonc.2020.11.011. Epub 2020 Nov 25. Ann Oncol. 2021. PMID: 33246021 Free article. Clinical Trial.
Management of pharmaceutical and recreational drug poisoning.
Mégarbane B, Oberlin M, Alvarez JC, Balen F, Beaune S, Bédry R, Chauvin A, Claudet I, Danel V, Debaty G, Delahaye A, Deye N, Gaulier JM, Grossenbacher F, Hantson P, Jacobs F, Jaffal K, Labadie M, Labat L, Langrand J, Lapostolle F, Le Conte P, Maignan M, Nisse P, Sauder P, Tournoud C, Vodovar D, Voicu S, Claret PG, Cerf C. Mégarbane B, et al. Among authors: le conte p. Ann Intensive Care. 2020 Nov 23;10(1):157. doi: 10.1186/s13613-020-00762-9. Ann Intensive Care. 2020. PMID: 33226502 Free PMC article. Review.
Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer.
Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S, Campone M, Blackwell KL, André F, Winer EP, Janni W, Verma S, Conte P, Arteaga CL, Cameron DA, Petrakova K, Hart LL, Villanueva C, Chan A, Jakobsen E, Nusch A, Burdaeva O, Grischke EM, Alba E, Wist E, Marschner N, Favret AM, Yardley D, Bachelot T, Tseng LM, Blau S, Xuan F, Souami F, Miller M, Germa C, Hirawat S, O'Shaughnessy J. Hortobagyi GN, et al. Among authors: conte p. N Engl J Med. 2016 Nov 3;375(18):1738-1748. doi: 10.1056/NEJMoa1609709. Epub 2016 Oct 7. N Engl J Med. 2016. PMID: 27717303 Free article. Clinical Trial.
The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial.
Sledge GW Jr, Toi M, Neven P, Sohn J, Inoue K, Pivot X, Burdaeva O, Okera M, Masuda N, Kaufman PA, Koh H, Grischke EM, Conte P, Lu Y, Barriga S, Hurt K, Frenzel M, Johnston S, Llombart-Cussac A. Sledge GW Jr, et al. Among authors: conte p. JAMA Oncol. 2020 Jan 1;6(1):116-124. doi: 10.1001/jamaoncol.2019.4782. JAMA Oncol. 2020. PMID: 31563959 Free PMC article.
Olaparib for the treatment of breast cancer.
Griguolo G, Dieci MV, Guarneri V, Conte P. Griguolo G, et al. Among authors: conte p. Expert Rev Anticancer Ther. 2018 Jun;18(6):519-530. doi: 10.1080/14737140.2018.1458613. Epub 2018 Mar 30. Expert Rev Anticancer Ther. 2018. PMID: 29582690 Review.
691 results